Acadia Pharmaceuticals (ACAD) said Friday a US district court ruled in its favor in formulation patent litigation against Aurobindo Pharma and other abbreviated new drug application filers.
The lawsuit involved Acadia's '721 formulation patent for Nuplazid, its treatment for Parkinson's disease psychosis.
The US District Court for the District of Delaware sided with Acadia on both infringement and validity arguments, the company said.
Shares of Acadia Pharmaceuticals were up more than 25% in recent trading.
Price: 22.09, Change: +4.49, Percent Change: +25.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.